QSant™ is a convenient, noninvasive, urine-based test that supports early detection of kidney rejection risk. By providing an actionable, individual risk score, it can empower clinicians to personalize care.
Early and accurate identification of rejection risk is critical for proactive management of transplant health.
Non-invasive screening should pave the way for earlier detection and intervention; however, most available blood-based tests fall short.
15 to 40%
of kidney transplants result in rejection
~10%
of kidney transplants every year are
re-transplants in patients with graft loss
QSant™ sets a new standard for non-invasive assessment of kidney transplant rejection
BIOMARKERS:
- Total Protein
- cfDNA
- m-cfDNA
- CXCL10
- Clusterin
- Creatinine
Q-Score
QSant Clinical Validation Papers
Clinical validation of a non-invasive, spot urine-based transplant rejection test that provides indication of risk of rejection earlier than standard-of-care tests.
601 samples
DOWNLOAD STM PAPER
PUBLISHED: 18 MARCH 2020
Development, validation, and clinical utility of a urinary Q-Score for the detection of acute rejection in adult and pediatric renal transplant patients
223 samples
DOWNLOAD MDPI PAPER
PUBLISHED: 22 JULY 2020
